OXYGENTA PHARMACEUTICAL LIMITED

Healthcare · Pharmaceuticals & Biotechnology

BSE: 524636
₹48.22
▲ 0.34 (0.71%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
24/100
Weak
Valuation
—/100
Data unavailable
Momentum
30/100
Bearish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹178 Cr
PE (TTM)
Data unavailable.
Price to Book
-4.2
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-46.5
Free Cash Flow
₹-41 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
65.45%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-7534.88%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
20.60%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-4.03%
as of Dec. 31, 2024
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
144.45%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
0.60
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
-2.57
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
-1.51
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
-3.43%
as of March 31, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
-0.13%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
-7.37%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
-8.23%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
-51.86%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
23.07%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

4 of 6 met
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (-2.57)
  • Yes Return on equity is 15% or more (23.1%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

1 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

0 of 4 met
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
0.7%
Low 47.5000 · High 49.1400
1W return
-3.9%
Low 46.1100 · High 51.4100
1M return
-14.0%
Low 46.1100 · High 58.7100
52W return
-46.5%
Low 46.1100 · High 71.5900
Lifetime High ₹90.1000 (Dec. 24, 2024)
Lifetime Low ₹3.0900 (July 21, 2008)

Full price history and technicals →

EMA & SMA

Bullish2
Bearish4
5D
48.9
10D
50.2
20D
51.9
50D
51.0
100D
46.6
200D
38.8

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
100.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

48.29
Pivot
First resistance49.07
Second resistance49.93
Third resistance50.71
First support47.43
Second support46.65
Third support45.79
Day RSI39.1
Day MFI17.6
Day MACD-1.67
Day MACD signal-0.89

Beta

1M0.14
3M-1.19
1Y-1.19
3Y0.36

Price change analysis

↓ -14.0%
Over 1 Month
LowHigh
46.1158.71
↓ -46.5%
Over 3 Months
LowHigh
46.1171.59
↓ -46.5%
Over 6 Months
LowHigh
46.1171.59
↓ -46.5%
Over 1 Year
LowHigh
46.1171.59
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Revenue (June 30, 2026)
₹37 Cr
Net profit (June 30, 2026)
₹— Cr
Basic EPS (June 30, 2026)
₹-0.5700

Ranks #123 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter56.54%
  • Mutual funds0.03%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 56.54% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings were unchanged at 0.03% in Jun 2026 qtr

All shareholding details →

DateClientDealActionQuantityPriceExchange
13 Feb 2026 VIRUPAKSHA ORGANICS LIMITED Bulk Buy 223,632 46.6000 BSE
13 Feb 2026 DEVARAPALLY VENKATESWARA REDDY Bulk Sell 300,000 46.9900 BSE
15 Dec 2025 VIRUPAKSHA ORGANICS LIMITED Bulk Buy 195,885 54.2500 BSE
15 Dec 2025 DEVARAPALLY VENKATESWARA REDDY Bulk Sell 204,472 54.3000 BSE
31 Jul 2018 INDRANEEL KANCHETI Bulk Buy 82,500 6.9900 BSE
11 Oct 2010 SRINIVAS REDDY K Bulk Sell 79,200 10.0600 BSE
27 Aug 2010 INDUSTRIAL DEVELOPMENT BANK OF INDIA Bulk Sell 39,900 6.7600 BSE
26 Dec 2008 SAMRAJYA LAKSHMI K Bulk Buy 45,500 4.8000 BSE
4 Sep 2008 P. L. BHARATHI Bulk Buy 100,000 8.5000 BSE
4 Sep 2008 ARYAVART SAVINGS UNIT LIMITED Bulk Sell 198,200 8.5000 BSE

All bulk and block deals →

Corporate Actions

Full history (1 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from S.S.Organics Ltd. to OXYGENTA PHARMACEUTICAL LIMITED

All corporate actions →

Corporate Announcements

All 2 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
1 Oct 2026 Company Update Oxygenta Pharmaceutical Ltd - 524636 - Announcement Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015-Purchase Of Land
29 Sep 2026 Insider Trading / SAST Oxygenta Pharmaceutical Ltd - 524636 - Closure of Trading Window

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong revenue growth YoY (144.4%)

Weaknesses

  • Thin net profit margin (-3.4%)
  • Negative shareholder equity (Debt/Equity -2.57) -- accumulated losses exceed paid-in capital
  • Tight liquidity (Current Ratio 0.60)
  • Declining profit YoY (-4.0%)

Opportunities

Data unavailable.

Threats

  • Down 46.5% over the past year
  • Weak interest coverage (-1.5x) -- limited cushion against rising rates

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about OXYGENTA PHARMACEUTICAL LIMITED

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.